NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

About NLS Pharmaceutics According to Kadimastem, the Hong Kong patent adds to previously granted patents in Europe, the United States and India, further strengthening the global protection around IsletRx. The patented process enables the selection and enrichment of highly functional islet cells from differentiated cell populations to help maximize therapeutic effect. Alexander Zwyer, Chief Executive Officer of NLS Pharmaceutics, commented: "We congratulate Kadimastem on this important intellectual property ...